Markets

Friday 7/17 Insider Buying Report: BCLI, PRSP

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

On Wednesday, Brainstorm Cell Therapeutics's Director, Sankesh Abbhi, made a $607,659 buy of BCLI, purchasing 46,779 shares at a cost of $12.99 a piece. Abbhi was up about 9.3% on the purchase at the high point of today's trading session, with BCLI trading as high as $14.20 at last check today. Brainstorm Cell Therapeutics is trading up about 4.8% on the day Friday. This buy marks the first one filed by Abbhi in the past year.

And also on Wednesday, Director, CEO John M. Curtis bought $403,237 worth of Perspecta, buying 18,354 shares at a cost of $21.97 a piece. This buy marks the first one filed by Curtis in the past year. Perspecta is trading up about 3.8% on the day Friday. Curtis was up about 8.2% on the buy at the high point of today's trading session, with PRSP trading as high as $23.77 in trading on Friday.

VIDEO: Friday 7/17 Insider Buying Report: BCLI, PRSP

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

BCLI

Other Topics

Stocks

Latest Markets Videos

BNK Invest

BNK Invest Inc. provides investment services and information. BNK Invest owns and operates a market news family of websites including DividendChannel, ETFChannel, StockOptionsChannel, and others, which make up an investor community featuring stock message boards, ratings, research, and strategies. BNK Invest caters to investing firms and individual investors internationally.

Learn More